TEE
BCLI

Tibra Equities Europe’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Tibra Equities Europe’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,800
Closed -$331K – 56
2021
Q2 		$331K Buy
+5,800
New +$310K 0.1% 113

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tibra Equities Europe's BCLI Position: Q3 2021 in Review

Tibra Equities Europe sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2021, closing a stake of 5,800 shares — an estimated $331K sold.

Tibra Equities Europe first reported a position in BCLI in Q2 2021 and held it in 1 quarter. The position peaked at $331K in Q2 2021. 52 funds tracked by Wall St. Rank hold BCLI as of Q3 2021.

  • Tibra Equities Europe reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 5,800 BRAINSTORM CELL THERAPUTC shares in Q3 2021, an estimated $331K.
  • Tibra Equities Europe first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's BRAINSTORM CELL THERAPUTC position peaked at $331K in Q2 2021.
  • 52 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.